Skybiotech Healthcare (512036) 주식 개요카필 코텍스는 인도에서 섬유 및 관련 사업을 영위하는 회사입니다. 자세히 보기512036 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장0/6과거 실적0/6재무 건전성0/6배당0/6위험 분석지난 5년간 매년 수익이 42.3% 감소했습니다.수익이 USD$1m 미만입니다(₹74M)cash runway 경력이 1년 미만입니다.의미 있는 시가총액이 없습니다(₹307M)+ 위험 1건 추가모든 위험 점검 보기512036 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW485,803 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA485,803 investors already sharing narrativesYour Fair Value₹Current Price₹160.1550.4% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-24m1b2016201920222025202620282031Revenue ₹1.1bEarnings ₹75.5mAdvancedSet Fair ValueView all narrativesSkybiotech Healthcare Limited 경쟁사Source Industries (India)Symbol: BSE:521036Market cap: ₹321.5mTatia Global VenntureSymbol: BSE:521228Market cap: ₹360.9mUnited CotfabSymbol: BSE:544195Market cap: ₹283.6mSihora IndustriesSymbol: BSE:544585Market cap: ₹314.3m가격 이력 및 성과Skybiotech Healthcare 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₹160.1552주 최고가₹237.3052주 최저가₹116.45베타-1.551개월 변동-19.91%3개월 변동n/a1년 변동-29.42%3년 변동113.53%5년 변동290.13%IPO 이후 변동487.71%최근 뉴스 및 업데이트Reported Earnings • Jun 01Full year 2026 earnings released: ₹6.70 loss per share (vs ₹12.37 loss in FY 2025)Full year 2026 results: ₹6.70 loss per share (improved from ₹12.37 loss in FY 2025). Revenue: ₹74.0m (flat on FY 2025). Net loss: ₹11.2m (loss narrowed 53% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.공고 • May 26Skybiotech Healthcare Limited to Report Q4, 2026 Results on May 30, 2026Skybiotech Healthcare Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026Board Change • May 26Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 16Third quarter 2026 earnings releasedThird quarter 2026 results: ₹1.29 loss per share. Revenue: ₹10.4m (down 61% from 3Q 2025). Net loss: ₹4.85m (loss widened 23% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 125 percentage points per year, which is a significant difference in performance.더 많은 업데이트 보기Recent updatesReported Earnings • Jun 01Full year 2026 earnings released: ₹6.70 loss per share (vs ₹12.37 loss in FY 2025)Full year 2026 results: ₹6.70 loss per share (improved from ₹12.37 loss in FY 2025). Revenue: ₹74.0m (flat on FY 2025). Net loss: ₹11.2m (loss narrowed 53% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.공고 • May 26Skybiotech Healthcare Limited to Report Q4, 2026 Results on May 30, 2026Skybiotech Healthcare Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026Board Change • May 26Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • May 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Apr 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Feb 16Third quarter 2026 earnings releasedThird quarter 2026 results: ₹1.29 loss per share. Revenue: ₹10.4m (down 61% from 3Q 2025). Net loss: ₹4.85m (loss widened 23% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 125 percentage points per year, which is a significant difference in performance.공고 • Feb 11Skybiotech Healthcare Limited to Report Q3, 2026 Results on Feb 14, 2026Skybiotech Healthcare Limited announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 14, 2026New Risk • Nov 18New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: ₹79m (US$889k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹14m free cash flow). Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (₹79m revenue, or US$889k). Market cap is less than US$10m (₹333.7m market cap, or US$3.76m).공고 • Nov 11Kapil Cotex Limited to Report Q2, 2026 Results on Nov 14, 2025Kapil Cotex Limited announced that they will report Q2, 2026 results on Nov 14, 2025공고 • Sep 26Kapil Cotex Limited Appoints Vijay Sitaram Chitlange as Non-Executive Independent DirectorKapil Cotex Limited at its AGM held on 25th September, 2025 announced appointment of Mr. Vijay Sitaram Chitlange (DIN: 11258669) as Non-Executive Independent Director.공고 • Aug 29Kapil Cotex Limited, Annual General Meeting, Sep 25, 2025Kapil Cotex Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time. Location: gut no.5,gavrai tanda, pattahan road, chh.sambhaji nagar, maharashtra 431002., IndiaNew Risk • Aug 16New major risk - Revenue and earnings growthEarnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹12m free cash flow). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (₹392.6m market cap, or US$4.49m). Minor Risk Revenue is less than US$5m (₹95m revenue, or US$1.1m).공고 • Aug 12Kapil Cotex Limited to Report Q1, 2026 Results on Aug 14, 2025Kapil Cotex Limited announced that they will report Q1, 2026 results on Aug 14, 2025Board Change • Aug 07Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.New Risk • Jul 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$1m (₹74m revenue, or US$866k). Market cap is less than US$10m (₹417.5m market cap, or US$4.86m).New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Revenue is less than US$1m (₹72m revenue, or US$838k). Market cap is less than US$10m (₹256.9m market cap, or US$2.99m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).공고 • May 27Kapil Cotex Limited to Report Q4, 2025 Results on May 30, 2025Kapil Cotex Limited announced that they will report Q4, 2025 results on May 30, 2025공고 • Mar 17Kapil Cotex Limited Announces Resignation of Nishi Jain as Company Secretary and Compliance OfficerKapil Cotex Limited informed that, the Company has received the resignation letter dated 17 March, 2025 from Mrs. Nishi Jain- Company Secretary and Compliance Officer of the company for resignation with effect from 17 March, 2025.Reported Earnings • Feb 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₹26.7m (up 95% from 3Q 2024). Net loss: ₹3.95m (down 137% from profit in 3Q 2024).공고 • Feb 12Kapil Cotex Limited to Report Q3, 2025 Results on Feb 14, 2025Kapil Cotex Limited announced that they will report Q3, 2025 results on Feb 14, 2025Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹219, the stock trades at a trailing P/E ratio of 42.7x. Average trailing P/E is 29x in the Luxury industry in India. Total returns to shareholders of 531% over the past three years.Valuation Update With 7 Day Price Move • Dec 22Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹334, the stock trades at a trailing P/E ratio of 65x. Average trailing P/E is 29x in the Luxury industry in India. Total returns to shareholders of 838% over the past three years.Valuation Update With 7 Day Price Move • Dec 07Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹275, the stock trades at a trailing P/E ratio of 53.5x. Average trailing P/E is 29x in the Luxury industry in India. Total returns to shareholders of 744% over the past three years.Valuation Update With 7 Day Price Move • Nov 22Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹228, the stock trades at a trailing P/E ratio of 44.3x. Average trailing P/E is 29x in the Luxury industry in India. Total returns to shareholders of 612% over the past three years.New Risk • Nov 16New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (152% accrual ratio). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Revenue is less than US$1m (₹59m revenue, or US$700k). Market cap is less than US$10m (₹535.2m market cap, or US$6.34m).공고 • Nov 08Kapil Cotex Limited to Report Q2, 2025 Results on Nov 14, 2024Kapil Cotex Limited announced that they will report Q2, 2025 results on Nov 14, 2024Valuation Update With 7 Day Price Move • Oct 31Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹200, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 30x in the Luxury industry in India. Total returns to shareholders of 544% over the past three years.공고 • Oct 09Kapil Cotex Limited Announces Resignation of Swati Maheshwari as Company Secretary and Compliance OfficerKapil Cotex Limited informed that Mrs. Swati Maheshwari, Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company, has submitted her resignation to pursue career opportunity outside the Organization and she will be relived with effect from October 1, 2024.공고 • Sep 12Kapil Cotex Limited, Annual General Meeting, Sep 30, 2024Kapil Cotex Limited, Annual General Meeting, Sep 30, 2024, at 11:30 Indian Standard Time. Location: gut no.5,gavrai tanda, pattahan road, chh.sambhaji nagar, maharashtra 431002., IndiaValuation Update With 7 Day Price Move • Aug 26Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹197, the stock trades at a trailing P/E ratio of 31.1x. Average trailing P/E is 37x in the Professional Services industry in India. Total returns to shareholders of 419% over the past three years.공고 • Aug 10Kapil Cotex Limited to Report Q1, 2025 Results on Aug 14, 2024Kapil Cotex Limited announced that they will report Q1, 2025 results on Aug 14, 2024Valuation Update With 7 Day Price Move • Jul 11Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹130, the stock trades at a trailing P/E ratio of 24.4x. Average trailing P/E is 31x in the Professional Services industry in India. Total returns to shareholders of 202% over the past three years.공고 • May 24Kapil Cotex Limited to Report Q4, 2024 Results on May 30, 2024Kapil Cotex Limited announced that they will report Q4, 2024 results on May 30, 2024New Risk • May 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (176% increase in shares outstanding). Revenue is less than US$1m (₹14m revenue, or US$168k). Market cap is less than US$10m (₹420.0m market cap, or US$5.03m). Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change).Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹139, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 27x in the Professional Services industry in India. Total returns to shareholders of 531% over the past three years.공고 • Apr 09Kapil Cotex Limited announced that it has received INR 66.7625 million in fundingOn April 8, 2024, Kapil Cotex Limited, closed the transaction. The company issued 875,000 common shares at a price of INR 76.3 per share for the gross proceeds of INR 66,762,500. The transaction included participation from Prakash Chandra Rathi for 500,000 shares, Raj Laxmi Ganesh Totala for 100,000 shares, Kaustubh Ashish Rathi for 62,500 shares, Sangita Ashish Rathi for 62,500 shares, Pavan Madanlal Malpani for 25,000 shares, Ganesh Shivprasad Lahoti for 85,000 shares, Smita Shivprasad Lahoti for 40,000 shares.공고 • Feb 10Kapil Cotex Limited to Report Q3, 2024 Results on Feb 14, 2024Kapil Cotex Limited announced that they will report Q3, 2024 results at 3:30 PM, Indian Standard Time on Feb 14, 2024New Risk • Feb 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 84% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Revenue is less than US$1m (₹314k revenue, or US$3.8k). Market cap is less than US$10m (₹266.8m market cap, or US$3.21m).Board Change • Jan 30Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • Oct 25Kapil Cotex Limited announced that it expects to receive INR 67.2 million in fundingKapil Cotex Limited announces private placement 9,60,000 equity shares at a price of INR 70 for gross proceeds of INR 67,200,000 on October 23, 2023.The shares will be issuing and allotting on preferential basis to 500000 shares to Prakash Chandra Rathi, 100000 shares to Raj Laxmi Ganesh Totala, 62500 shares to Kaustubh Ashish Rathi, 62500 shares to Sangita Ashish Rathi, 55000 shares to Pavan Madanlal Malpani, 55000 shares to Dhanshree Yogesh Malpani, 85000 shares to Ganesh Shivprasad Lahoti and 40000 shares to Smita Shivprasad Lahoti.공고 • Sep 03Kapil Cotex Limited, Annual General Meeting, Sep 30, 2023Kapil Cotex Limited, Annual General Meeting, Sep 30, 2023, at 10:00 Indian Standard Time. Location: 17A, Miniland Gate No 4 Tank Road, Bhandup (West), Mumbai Mumbai India Agenda: To receive, consider and adopt the audited financial statement of the Company for the financial year ended 31st March 2023, and report of the Board of Directors and Auditors thereon; To appoint a Director in place of Mr. Yogesh Chandak who retires by rotation, and being eligible offers himself for re-appointment.공고 • Aug 07Kapil Cotex Limited to Report Q1, 2024 Results on Aug 14, 2023Kapil Cotex Limited announced that they will report Q1, 2024 results on Aug 14, 2023Board Change • Feb 28Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • Feb 08Kapil Cotex Limited to Report Q3, 2023 Results on Feb 14, 2023Kapil Cotex Limited announced that they will report Q3, 2023 results on Feb 14, 2023Board Change • Jan 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Nov 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.공고 • Sep 11Kapil Cotex Limited, Annual General Meeting, Sep 30, 2022Kapil Cotex Limited, Annual General Meeting, Sep 30, 2022, at 10:00 Indian Standard Time.공고 • Aug 08Kapil Cotex Limited to Report Q1, 2023 Results on Aug 13, 2022Kapil Cotex Limited announced that they will report Q1, 2023 results on Aug 13, 2022Board Change • Jul 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Board Change • Sep 30Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Is New 90 Day High Low • Feb 23New 90-day low: ₹19.90The company is down 5.0% from its price of ₹20.90 on 25 November 2020. The Indian market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Professional Services industry, which is up 27% over the same period.공고 • Feb 02Kapil Cotex Limited to Report Q3, 2021 Results on Feb 13, 2021Kapil Cotex Limited announced that they will report Q3, 2021 results on Feb 13, 2021공고 • Jul 26Kapil Cotex Limited to Report Q1, 2021 Results on Jul 24, 2020Kapil Cotex Limited announced that they will report Q1, 2021 results on Jul 24, 2020공고 • Jul 05Kapil Cotex Limited to Report Q4, 2020 Results on Jun 30, 2020Kapil Cotex Limited announced that they will report Q4, 2020 results on Jun 30, 2020주주 수익률512036IN LuxuryIN 시장7D23.2%-0.1%-1.4%1Y-29.4%9.2%-0.2%전체 주주 수익률 보기수익률 대 산업: 512036은 지난 1년 동안 9.2%의 수익을 기록한 Indian Luxury 산업보다 저조한 성과를 냈습니다.수익률 대 시장: 512036은 지난 1년 동안 -0.2%를 기록한 Indian 시장보다 저조한 성과를 냈습니다.주가 변동성Is 512036's price volatile compared to industry and market?512036 volatility512036 Average Weekly Movement8.6%Luxury Industry Average Movement6.1%Market Average Movement6.0%10% most volatile stocks in IN Market9.0%10% least volatile stocks in IN Market3.7%안정적인 주가: 512036의 주가는 지난 3개월 동안 Indian 시장보다 변동성이 컸습니다.시간에 따른 변동성: 512036의 주간 변동성(9%)은 지난 1년 동안 안정적이었지만 Indian 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트1983n/aPoonam Rathiwww.kapilcotexlimited.com카필 코텍스는 인도에서 섬유 및 관련 사업을 영위하고 있습니다. 이 회사는 주식과 증권도 취급합니다. 카필 코텍스는 1983년에 설립되었으며 인도 아우랑가바드에 본사를 두고 있습니다.더 보기Skybiotech Healthcare Limited 기초 지표 요약Skybiotech Healthcare의 순이익과 매출은 시가총액과 어떻게 비교됩니까?512036 기초 통계시가총액₹306.69m순이익 (TTM)-₹11.17m매출 (TTM)₹74.04m4.1x주가매출비율(P/S)-27.5x주가수익비율(P/E)512036는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표512036 손익계산서 (TTM)매출₹74.04m매출원가₹39.10m총이익₹34.94m기타 비용₹46.11m순이익-₹11.17m최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-5.83총이익률47.19%순이익률-15.08%부채/자본 비율90.9%512036의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/26 05:25종가2026/07/24 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Skybiotech Healthcare Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Reported Earnings • Jun 01Full year 2026 earnings released: ₹6.70 loss per share (vs ₹12.37 loss in FY 2025)Full year 2026 results: ₹6.70 loss per share (improved from ₹12.37 loss in FY 2025). Revenue: ₹74.0m (flat on FY 2025). Net loss: ₹11.2m (loss narrowed 53% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
공고 • May 26Skybiotech Healthcare Limited to Report Q4, 2026 Results on May 30, 2026Skybiotech Healthcare Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
Board Change • May 26Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 16Third quarter 2026 earnings releasedThird quarter 2026 results: ₹1.29 loss per share. Revenue: ₹10.4m (down 61% from 3Q 2025). Net loss: ₹4.85m (loss widened 23% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 125 percentage points per year, which is a significant difference in performance.
Reported Earnings • Jun 01Full year 2026 earnings released: ₹6.70 loss per share (vs ₹12.37 loss in FY 2025)Full year 2026 results: ₹6.70 loss per share (improved from ₹12.37 loss in FY 2025). Revenue: ₹74.0m (flat on FY 2025). Net loss: ₹11.2m (loss narrowed 53% from FY 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 62 percentage points per year, which is a significant difference in performance.
공고 • May 26Skybiotech Healthcare Limited to Report Q4, 2026 Results on May 30, 2026Skybiotech Healthcare Limited announced that they will report Q4, 2026 results at 12:15 PM, Indian Standard Time on May 30, 2026
Board Change • May 26Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • May 11Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Apr 08Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Non-Executive Independent Director Vijay Chitlange was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Feb 16Third quarter 2026 earnings releasedThird quarter 2026 results: ₹1.29 loss per share. Revenue: ₹10.4m (down 61% from 3Q 2025). Net loss: ₹4.85m (loss widened 23% from 3Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 125 percentage points per year, which is a significant difference in performance.
공고 • Feb 11Skybiotech Healthcare Limited to Report Q3, 2026 Results on Feb 14, 2026Skybiotech Healthcare Limited announced that they will report Q3, 2026 results at 3:30 PM, Indian Standard Time on Feb 14, 2026
New Risk • Nov 18New major risk - Revenue sizeThe company makes less than US$1m in revenue. Total revenue: ₹79m (US$889k) This is considered a major risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹14m free cash flow). Share price has been highly volatile over the past 3 months (9.4% average weekly change). Earnings have declined by 33% per year over the past 5 years. Revenue is less than US$1m (₹79m revenue, or US$889k). Market cap is less than US$10m (₹333.7m market cap, or US$3.76m).
공고 • Nov 11Kapil Cotex Limited to Report Q2, 2026 Results on Nov 14, 2025Kapil Cotex Limited announced that they will report Q2, 2026 results on Nov 14, 2025
공고 • Sep 26Kapil Cotex Limited Appoints Vijay Sitaram Chitlange as Non-Executive Independent DirectorKapil Cotex Limited at its AGM held on 25th September, 2025 announced appointment of Mr. Vijay Sitaram Chitlange (DIN: 11258669) as Non-Executive Independent Director.
공고 • Aug 29Kapil Cotex Limited, Annual General Meeting, Sep 25, 2025Kapil Cotex Limited, Annual General Meeting, Sep 25, 2025, at 11:00 Indian Standard Time. Location: gut no.5,gavrai tanda, pattahan road, chh.sambhaji nagar, maharashtra 431002., India
New Risk • Aug 16New major risk - Revenue and earnings growthEarnings have declined by 21% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₹12m free cash flow). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Earnings have declined by 21% per year over the past 5 years. Market cap is less than US$10m (₹392.6m market cap, or US$4.49m). Minor Risk Revenue is less than US$5m (₹95m revenue, or US$1.1m).
공고 • Aug 12Kapil Cotex Limited to Report Q1, 2026 Results on Aug 14, 2025Kapil Cotex Limited announced that they will report Q1, 2026 results on Aug 14, 2025
Board Change • Aug 07Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
New Risk • Jul 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (8.4% average weekly change). Revenue is less than US$1m (₹74m revenue, or US$866k). Market cap is less than US$10m (₹417.5m market cap, or US$4.86m).
New Risk • Jun 05New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Revenue is less than US$1m (₹72m revenue, or US$838k). Market cap is less than US$10m (₹256.9m market cap, or US$2.99m). Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change).
공고 • May 27Kapil Cotex Limited to Report Q4, 2025 Results on May 30, 2025Kapil Cotex Limited announced that they will report Q4, 2025 results on May 30, 2025
공고 • Mar 17Kapil Cotex Limited Announces Resignation of Nishi Jain as Company Secretary and Compliance OfficerKapil Cotex Limited informed that, the Company has received the resignation letter dated 17 March, 2025 from Mrs. Nishi Jain- Company Secretary and Compliance Officer of the company for resignation with effect from 17 March, 2025.
Reported Earnings • Feb 17Third quarter 2025 earnings releasedThird quarter 2025 results: Revenue: ₹26.7m (up 95% from 3Q 2024). Net loss: ₹3.95m (down 137% from profit in 3Q 2024).
공고 • Feb 12Kapil Cotex Limited to Report Q3, 2025 Results on Feb 14, 2025Kapil Cotex Limited announced that they will report Q3, 2025 results on Feb 14, 2025
Valuation Update With 7 Day Price Move • Jan 24Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ₹219, the stock trades at a trailing P/E ratio of 42.7x. Average trailing P/E is 29x in the Luxury industry in India. Total returns to shareholders of 531% over the past three years.
Valuation Update With 7 Day Price Move • Dec 22Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ₹334, the stock trades at a trailing P/E ratio of 65x. Average trailing P/E is 29x in the Luxury industry in India. Total returns to shareholders of 838% over the past three years.
Valuation Update With 7 Day Price Move • Dec 07Investor sentiment improves as stock rises 28%After last week's 28% share price gain to ₹275, the stock trades at a trailing P/E ratio of 53.5x. Average trailing P/E is 29x in the Luxury industry in India. Total returns to shareholders of 744% over the past three years.
Valuation Update With 7 Day Price Move • Nov 22Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ₹228, the stock trades at a trailing P/E ratio of 44.3x. Average trailing P/E is 29x in the Luxury industry in India. Total returns to shareholders of 612% over the past three years.
New Risk • Nov 16New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (152% accrual ratio). Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Revenue is less than US$1m (₹59m revenue, or US$700k). Market cap is less than US$10m (₹535.2m market cap, or US$6.34m).
공고 • Nov 08Kapil Cotex Limited to Report Q2, 2025 Results on Nov 14, 2024Kapil Cotex Limited announced that they will report Q2, 2025 results on Nov 14, 2024
Valuation Update With 7 Day Price Move • Oct 31Investor sentiment improves as stock rises 15%After last week's 15% share price gain to ₹200, the stock trades at a trailing P/E ratio of 20.9x. Average trailing P/E is 30x in the Luxury industry in India. Total returns to shareholders of 544% over the past three years.
공고 • Oct 09Kapil Cotex Limited Announces Resignation of Swati Maheshwari as Company Secretary and Compliance OfficerKapil Cotex Limited informed that Mrs. Swati Maheshwari, Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company, has submitted her resignation to pursue career opportunity outside the Organization and she will be relived with effect from October 1, 2024.
공고 • Sep 12Kapil Cotex Limited, Annual General Meeting, Sep 30, 2024Kapil Cotex Limited, Annual General Meeting, Sep 30, 2024, at 11:30 Indian Standard Time. Location: gut no.5,gavrai tanda, pattahan road, chh.sambhaji nagar, maharashtra 431002., India
Valuation Update With 7 Day Price Move • Aug 26Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹197, the stock trades at a trailing P/E ratio of 31.1x. Average trailing P/E is 37x in the Professional Services industry in India. Total returns to shareholders of 419% over the past three years.
공고 • Aug 10Kapil Cotex Limited to Report Q1, 2025 Results on Aug 14, 2024Kapil Cotex Limited announced that they will report Q1, 2025 results on Aug 14, 2024
Valuation Update With 7 Day Price Move • Jul 11Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹130, the stock trades at a trailing P/E ratio of 24.4x. Average trailing P/E is 31x in the Professional Services industry in India. Total returns to shareholders of 202% over the past three years.
공고 • May 24Kapil Cotex Limited to Report Q4, 2024 Results on May 30, 2024Kapil Cotex Limited announced that they will report Q4, 2024 results on May 30, 2024
New Risk • May 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (176% increase in shares outstanding). Revenue is less than US$1m (₹14m revenue, or US$168k). Market cap is less than US$10m (₹420.0m market cap, or US$5.03m). Minor Risk Share price has been volatile over the past 3 months (8.2% average weekly change).
Valuation Update With 7 Day Price Move • May 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹139, the stock trades at a trailing P/E ratio of 38.2x. Average trailing P/E is 27x in the Professional Services industry in India. Total returns to shareholders of 531% over the past three years.
공고 • Apr 09Kapil Cotex Limited announced that it has received INR 66.7625 million in fundingOn April 8, 2024, Kapil Cotex Limited, closed the transaction. The company issued 875,000 common shares at a price of INR 76.3 per share for the gross proceeds of INR 66,762,500. The transaction included participation from Prakash Chandra Rathi for 500,000 shares, Raj Laxmi Ganesh Totala for 100,000 shares, Kaustubh Ashish Rathi for 62,500 shares, Sangita Ashish Rathi for 62,500 shares, Pavan Madanlal Malpani for 25,000 shares, Ganesh Shivprasad Lahoti for 85,000 shares, Smita Shivprasad Lahoti for 40,000 shares.
공고 • Feb 10Kapil Cotex Limited to Report Q3, 2024 Results on Feb 14, 2024Kapil Cotex Limited announced that they will report Q3, 2024 results at 3:30 PM, Indian Standard Time on Feb 14, 2024
New Risk • Feb 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 84% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (84% increase in shares outstanding). Revenue is less than US$1m (₹314k revenue, or US$3.8k). Market cap is less than US$10m (₹266.8m market cap, or US$3.21m).
Board Change • Jan 30Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • Oct 25Kapil Cotex Limited announced that it expects to receive INR 67.2 million in fundingKapil Cotex Limited announces private placement 9,60,000 equity shares at a price of INR 70 for gross proceeds of INR 67,200,000 on October 23, 2023.The shares will be issuing and allotting on preferential basis to 500000 shares to Prakash Chandra Rathi, 100000 shares to Raj Laxmi Ganesh Totala, 62500 shares to Kaustubh Ashish Rathi, 62500 shares to Sangita Ashish Rathi, 55000 shares to Pavan Madanlal Malpani, 55000 shares to Dhanshree Yogesh Malpani, 85000 shares to Ganesh Shivprasad Lahoti and 40000 shares to Smita Shivprasad Lahoti.
공고 • Sep 03Kapil Cotex Limited, Annual General Meeting, Sep 30, 2023Kapil Cotex Limited, Annual General Meeting, Sep 30, 2023, at 10:00 Indian Standard Time. Location: 17A, Miniland Gate No 4 Tank Road, Bhandup (West), Mumbai Mumbai India Agenda: To receive, consider and adopt the audited financial statement of the Company for the financial year ended 31st March 2023, and report of the Board of Directors and Auditors thereon; To appoint a Director in place of Mr. Yogesh Chandak who retires by rotation, and being eligible offers himself for re-appointment.
공고 • Aug 07Kapil Cotex Limited to Report Q1, 2024 Results on Aug 14, 2023Kapil Cotex Limited announced that they will report Q1, 2024 results on Aug 14, 2023
Board Change • Feb 28Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • Feb 08Kapil Cotex Limited to Report Q3, 2023 Results on Feb 14, 2023Kapil Cotex Limited announced that they will report Q3, 2023 results on Feb 14, 2023
Board Change • Jan 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Nov 18Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
공고 • Sep 11Kapil Cotex Limited, Annual General Meeting, Sep 30, 2022Kapil Cotex Limited, Annual General Meeting, Sep 30, 2022, at 10:00 Indian Standard Time.
공고 • Aug 08Kapil Cotex Limited to Report Q1, 2023 Results on Aug 13, 2022Kapil Cotex Limited announced that they will report Q1, 2023 results on Aug 13, 2022
Board Change • Jul 15Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Apr 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Board Change • Sep 30Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Jagdish Mantri was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Is New 90 Day High Low • Feb 23New 90-day low: ₹19.90The company is down 5.0% from its price of ₹20.90 on 25 November 2020. The Indian market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Professional Services industry, which is up 27% over the same period.
공고 • Feb 02Kapil Cotex Limited to Report Q3, 2021 Results on Feb 13, 2021Kapil Cotex Limited announced that they will report Q3, 2021 results on Feb 13, 2021
공고 • Jul 26Kapil Cotex Limited to Report Q1, 2021 Results on Jul 24, 2020Kapil Cotex Limited announced that they will report Q1, 2021 results on Jul 24, 2020
공고 • Jul 05Kapil Cotex Limited to Report Q4, 2020 Results on Jun 30, 2020Kapil Cotex Limited announced that they will report Q4, 2020 results on Jun 30, 2020
